Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer

Natacha Bordry; Alfredo Addeo; Cyril Jaksic; Valérie Dutoit; Pascale Roux-Lombard; Dimpy P. Shah; Pankil K. Shah; Angèle Gayet-Ageron; Alex Friedlaender; Sébastien Bugeia; Garance Gutknecht; Anna Battagin; Maragrazia Di Marco; Pierre Francois Simand; Intidhar Ladibi-Galy; Sarah Fertani; José Sandoval; Pierre Yves Dietrich; Nicolas Mach

doi:10.1016/j.isci.2021.103699

Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer

Natacha Bordry, Alfredo Addeo, Cyril Jaksic, Valérie Dutoit, Pascale Roux-Lombard, Dimpy P. Shah, Pankil K. Shah, Angèle Gayet-Ageron, Alex Friedlaender, Sébastien Bugeia, Garance Gutknecht, Anna Battagin, Maragrazia Di Marco, Pierre Francois Simand, Intidhar Ladibi-Galy, Sarah Fertani, José Sandoval, Pierre Yves Dietrich, Nicolas Mach

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients.

Original language	English (US)
Article number	103699
Journal	iScience
Volume	25
Issue number	1
DOIs	https://doi.org/10.1016/j.isci.2021.103699
State	Published - Jan 21 2022
Externally published	Yes

Keywords

Biological sciences
Immune response
Virology

ASJC Scopus subject areas

General

Access to Document

10.1016/j.isci.2021.103699

Cite this

Bordry, N., Addeo, A., Jaksic, C., Dutoit, V., Roux-Lombard, P., Shah, D. P., Shah, P. K., Gayet-Ageron, A., Friedlaender, A., Bugeia, S., Gutknecht, G., Battagin, A., Di Marco, M., Simand, P. F., Ladibi-Galy, I., Fertani, S., Sandoval, J., Dietrich, P. Y., & Mach, N. (2022). Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer. iScience, 25(1), Article 103699. https://doi.org/10.1016/j.isci.2021.103699

Bordry, N, Addeo, A, Jaksic, C, Dutoit, V, Roux-Lombard, P, Shah, DP , Shah, PK, Gayet-Ageron, A, Friedlaender, A, Bugeia, S, Gutknecht, G, Battagin, A, Di Marco, M, Simand, PF, Ladibi-Galy, I, Fertani, S, Sandoval, J, Dietrich, PY & Mach, N 2022, 'Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer', iScience, vol. 25, no. 1, 103699. https://doi.org/10.1016/j.isci.2021.103699

@article{40a36d0347f942a8a88e93f29ae0a0ca,

title = "Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer",

abstract = "Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients.",

keywords = "Biological sciences, Immune response, Virology",

author = "Natacha Bordry and Alfredo Addeo and Cyril Jaksic and Val{\'e}rie Dutoit and Pascale Roux-Lombard and Shah, {Dimpy P.} and Shah, {Pankil K.} and Ang{\`e}le Gayet-Ageron and Alex Friedlaender and S{\'e}bastien Bugeia and Garance Gutknecht and Anna Battagin and {Di Marco}, Maragrazia and Simand, {Pierre Francois} and Intidhar Ladibi-Galy and Sarah Fertani and Jos{\'e} Sandoval and Dietrich, {Pierre Yves} and Nicolas Mach",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = jan,

day = "21",

doi = "10.1016/j.isci.2021.103699",

language = "English (US)",

volume = "25",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer

AU - Bordry, Natacha

AU - Addeo, Alfredo

AU - Jaksic, Cyril

AU - Dutoit, Valérie

AU - Roux-Lombard, Pascale

AU - Shah, Dimpy P.

AU - Shah, Pankil K.

AU - Gayet-Ageron, Angèle

AU - Friedlaender, Alex

AU - Bugeia, Sébastien

AU - Gutknecht, Garance

AU - Battagin, Anna

AU - Di Marco, Maragrazia

AU - Simand, Pierre Francois

AU - Ladibi-Galy, Intidhar

AU - Fertani, Sarah

AU - Sandoval, José

AU - Dietrich, Pierre Yves

AU - Mach, Nicolas

PY - 2022/1/21

Y1 - 2022/1/21

N2 - Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients.

AB - Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients.

KW - Biological sciences

KW - Immune response

KW - Virology

UR - http://www.scopus.com/inward/record.url?scp=85122540081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122540081&partnerID=8YFLogxK

U2 - 10.1016/j.isci.2021.103699

DO - 10.1016/j.isci.2021.103699

M3 - Article

C2 - 34977496

AN - SCOPUS:85122540081

SN - 2589-0042

VL - 25

JO - iScience

JF - iScience

IS - 1

M1 - 103699

ER -

Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this